

12th July 2010

Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza
Bandra, Kurla Complex
Bandra (E)
Mumbai – 400 051

Dear Sir,

“SUVEN EQ”

Sub : Press Release

Please find enclosed press release of our Company titled **“Suven Life Sciences presenting at International Conference on Alzheimer’s disease (ICAD).”**

This is for your information and records

Thanking you,
Yours faithfully,
For Suven Life Sciences Ltd


K. Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Regd. Office: Serene Chambers, Road # 5, Avenue 7, Banjara Hills, Hyderabad 500 034, INDIA

Tel: 91-40-2354 1142/ 3311, 3292 1695/ 96, Fax: 91-40-2354 1152

info@suven.com

www.suven.com



News Release

Suven Life Sciences presenting at International Conference on Alzheimer's Disease (ICAD)

HYDERABAD, INDIA (Jul 12, 2010) – Several exciting new results and data presentations from **Suven's** portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at **International Conference on Alzheimer's Disease (ICAD)** at Honolulu, USA during the week of July 12-15, 2010. ICAD is the annual International conference of the **Alzheimer's association** and more than 10 thousand Neuro Scientists, clinicians, corporate senior management from all over the world covering all the major Pharma, Biotech and Academic research Institutions would attend this meeting.

Suven's portfolio has an excellent new molecule which not only treats the cognitive impairment in Alzheimer's disease symptomatically but also possibly useful in reducing the disease progression. Suven scientists are presenting exciting data on this molecule and other NCE's on cognitive impairment and memory related disorders, depression and pain.

Alzheimer's disease has a significant unmet medical need for which current treatment options are insufficient. Suven has a number of in-house drug discovery programs in the area of cognition, focusing on novel approaches that may lead to the development of new therapies for patients in addition to the current clinical candidate SUVN-502.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates** currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to **developmental candidate SUVN-502** for Alzheimer's disease and Schizophrenia.

Suven is committed to neuroscience research and is **"In search of new CNS therapies for better living."**

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

